Advanced Accelerator Applications, a Novartis company
Advanced Accelerator Applications (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology.
Agendia
Committed to the best science, our genomic tests increase confidence when choosing a breast cancer treatment path. MammaPrint is the well-known risk of recurrence test and BluePrint provides molecular subtyping.
Alkermes, Inc.
Alkermes plc is a fully integrated global biopharmaceutical company, with a portfolio of commercial products in addiction and schizophrenia. Alkermes’ pipeline includes candidates for cancer, schizophrenia, bipolar I disorder and neurodegenerative disorders.
Bayer
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments.
Biognosys
Biognosys provides customized contract research services using our proprietary next-generation mass spectrometry workflows and data analysis to provide novel insights across drug discovery and development, pre-clinical, and clinical studies.
Boehringer Ingelheim International GmbH
At Boehringer Ingelheim we are taking cancer on, collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com.
Calithera Biosciences
Calithera is pioneering the discovery of small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity. Telaglenastat, a glutaminase inhibitor, is in clinical trials.
Caris Life Sciences
Caris Life Sciences, a leading innovator in molecular science, provides market-leading molecular profiling offerings that assess DNA, RNA and proteins to guide more precise and personalized treatment decisions.
- carisvirtualexhibit.com
CeGaT
CeGaT is a leading provider of genetic tumour diagnostics. We support oncologists in choosing the optimal therapeutic strategy. We provide a detailed analysis of somatic mutations and determination of TMB and MSI for further treatment options.
COR2ED
COR2ED develops and implements impactful independent medical education programmes, improving the knowledge and changing the behaviour of healthcare professionals globally.
Daiichi Sankyo
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.
Eisai Europe LTD.
Eisai is a global research and development-based pharmaceutical company. We strive to realise our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.
Eli Lilly and Company
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. We’re determined to continue making life better for those affected by cancer around the world.
Exact Sciences
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. For more information, please visit the company’s website at www.exactsciences.com.
Exelixis Inc.
Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.
F. Hoffmann-La Roche Ltd
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s leading provider of cancer care products, including anti-cancer treatments, supportive care products and diagnostics.
Genmab
Genmab is a publicly traded, international biotechnology company. Genmab specializes in the creation and development of differentiated antibody therapeutics and has a broad clinical and pre-clinical product pipeline.
GSK
GSK is committed to maximizing patient survival through transformational medicines. Our pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality with the goal of achieving a diverse portfolio of medicines.
Guardant Health
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests. Guardant360 liquid biopsy comprehensive genomic profiling helps clinicians guide treatment decisions in 7 days.
Immunomedics
Immunomedics is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers.
Incyte
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information, please visit Incyte.com.
Ipsen
Ipsen is a leading global biopharmaceutical company focused on Innovation and Specialty Care. It develops and commercializes medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases.
Janssen
At Janssen, we’re creating a future where disease is a thing of the past. We work tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.
Kite, a Gilead company
Kite, a Gilead Company, is based in Santa Monica, California, with operations globally. Kite develops of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.
Med Learning Group
The IC-ONC VR room invites learners to investigate PD-1 blockade in dMMR/MSI tumors & common irAEs that may result from checkpoint blockade. IC-ONC.org is a central hub for resources & information pertinent to cancer treatment with immunotherapy.
Medscape
Medscape is the leading online global destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME.
Menarini Silicon Biosystems
Menarini Silicon Biosystems offers unique rare cell technologies CELLSEARCH® and DEPArray™ that together are able to provide an end-to-end workflow solution for the enumeration, isolation, and molecular characterization of CTCs in liquid biopsy.
Merck
For more information about Merck visit www.merckgroup.com
MSD
MSD is a leading research-intensive biopharmaceutical company at the forefront of innovative research aimed at delivering health solutions and advancing the prevention and treatment of challenging diseases around the world.
Myriad Genetics
Myriad Genetics is a pioneer in molecular diagnostics, offering innovative products that change patients’ lives. Our tests guide treatment decisions in eight cancer types, including the gold standard in PARPi companion diagnostics: myChoice CDx.
Natera
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients diagnosed with cancer. Signatera has been clinically validated in multiple cancer types.
Oncompass Medicine
Full Precision Oncology Care Solution: Diagnostics NGS600-WES/IHC/MSI/CNV; Molecular profile-based AI digital drug assignment; Personalized targeted & immunotherapy planning; Virtual Molecular Tumor Board; Clinical trial & therapy access support.
OSE Immunotherapeutics
OSE Immunotherapeutics is a French clinical-stage biotechnology company focused on research and development of innovative immunotherapies in immuno-oncology and autoimmune diseases and partnering them with academic research and pharmaceutical companies.
Pfizer Oncology
We are committed to advancing medicines wherever we believe we can make a meaningful difference for patients. Today, Pfizer Oncology has an industry-leading portfolio of 23 approved innovative cancer medicines & biosimilars across more than 30 indications.
PharmaMar
PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. PharmaMar develops and commercializes Yondelis® in Europe.
Philips Molecular Pathway Diagnostics
Philips Molecular Pathway Dx commercializes OncoSignal molecular tests that quantify the activity of cell signal transduction pathways. OncoSignal can be applied for drug response monitoring (RUO), stratification for clinical trials and for cancer research.
Pierre Fabre
Pierre Fabre is a French pharmaceutical and dermo-cosmetical company operating in more than 45 countries. 35-year experience in innovation, development, manufacturing and commercialization has brought Pierre Fabre international recognition in oncology.
Precision for Medicine
Precision is the first full service clinical research organisation purpose-built to improve the clinical research process for new therapeutics. Our novel approach integrates clinical operations with laboratory expertise and advanced data sciences.
QED Therapeutics
Therapeutics is dedicated to the development of infigratinib, a selective tyrosine kinase inhibitor. Infigratinib is under investigation for cholangiocarcinoma, and urothelial carcinoma.
Q² Solutions
Q2 Solutions is a global leader in clinical trial laboratory services with secure, enterprise-wide biospecimen and consent management solutions. Focusing on quality and innovation, Q2 Solutions treats each sample as if a life depends on it.
Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its IlluminoxTM technology platform.
Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company and antibody research pioneer, inventing life-transforming medicines for people with serious diseases. Our areas of focus include cancer, inflammation, pain, ophthalmology, and infectious diseases.
Sanofi Genzyme
Sanofi Genzyme focuses on developing therapies in oncology, rare diseases, rare blood disorders, multiple sclerosis, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat.
Seattle Genetics
A global biotechnology company that discovers, develops and commercializes cancer medicines, and has a pipeline at various stages of preclinical testing and clinical development. Headquartered in the US, with international operations in Switzerland.
Servier
Servier is an independent pharmaceutical company with a strong international presence in 150 countries. Committed to fighting cancer, the Group intends to dedicate 50% of its global R&D budget to researching cancer treatments.
Stemline
Stemline is dedicated to raising awareness of blastic plasmacytoid dendritic cell neoplasm (BPDCN)—a hematologic cancer that can be dangerously unseen.
Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Learn how we help customers shorten the distance from lab to life® at syneoshealth.com.
Taiho Oncology, Inc.
Taiho Oncology, Inc., has established a world class clinical development organization that works urgently to develop innovative cancer treatments, with an oral oncology pipeline consisting of novel antimetabolic agents and selectively targeted agents.
Takeda Oncology
Takeda is a patient-focused, innovation-driven global pharmaceutical company that builds on a distinguished 237-year history. We are committed to bringing Better Health and a Brighter Future to people worldwide. Learn more at www.takedaoncology.com
UNICANCER
Unicancer is the only French hospital network that is dedicated entirely to fighting cancer, with 18 cancer research centers, private health non-profit institutes. Unicancer is also Europe’s leading academic promoter of clinical trials in oncology.
WeHealthTM Digital Medicine
Launched in November 2016, WeHealth™ Digital Medicine is a digital health innovator which aims at supporting healthcare professionals & transforming the patient’s journey using digital solutions.
2cureX
Copenhagen-based 2cureX are the innovators of IndiTreat®, the world’s first IVD CE validated cancer sensitivity test based on patient derived microtumors. IndiTreat® provides data for improving cancer treatment, in accordance with national guidelines.